A biotech company aiming to simplify chronic care through advanced transdermal drug delivery has secured $12.6M in Series A funding. Anodyne Nanotech, Inc. specializes in making existing and emerging large molecule treatments more accessible, particularly for multi-milligram doses and complex formulations.
The clinical-stage company's proprietary HeroPatch technology represents a breakthrough in drug delivery, enabling tunable pharmacokinetic profiles and room temperature stability for next-generation therapeutics. Anodyne's initial product pipeline is focused on addressing the unmet needs of chronic diseases, with an early emphasis on obesity.
